AbbVie reported on Friday fourth quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
AbbVie announced earnings per share of $2.21 on revenue of $8.70B. Analysts polled by anticipated EPS of $2.19 on revenue of $8.7B. That with comparison to EPS of $1.9 on revenue of $8.31B in the same period a year before. AbbVie had reported EPS of $2.33 on revenue of $8.48B in the previous quarter. Analysts are expecting EPS of $2.11 and revenue of $8.02B in the upcoming quarter.
AbbVie shares are down 1% from the beginning of the year , still down 5.23% from its 52 week high of $91.99 set on December 20, 2019. They are under-performing the S&P 500 which is up 3.12% year to date.
AbbVie shares gained 1.86% in pre-market trade after the report.
AbbVie follows other major Healthcare sector earnings this month
AbbVie's report follows an earnings beat by J&J on January 22, who reported EPS of $1.88 on revenue of $20.75B, compared to forecasts EPS of $1.87 on revenue of $20.8B.
Novartis ADR had beat expectations on January 29 with fourth quarter EPS of $1.32 on revenue of $12.4B, compared to forecast for EPS of $1.31 on revenue of $12.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting 's earnings calendar
